Prostate Cancer

External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer. October 7, 2022

Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL. October 7, 2022

Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma. October 7, 2022

Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest. October 7, 2022

Cytoreductive radical prostatectomy or radiation therapy for metastases prostate cancer: Evidence from meta-analysis. October 7, 2022

The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey. October 6, 2022

Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. October 6, 2022

Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel. October 6, 2022

Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy. October 6, 2022

Magnetic Resonance Imaging-targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer. October 6, 2022

Targeted Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy for Quantitative Gleason 4 Grading Prediction in Radical Prostatectomy Specimens: Implications for Active Surveillance Candidate Selection. October 5, 2022

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. October 5, 2022

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer. October 5, 2022

Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study. October 5, 2022

Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives. October 5, 2022

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial October 4, 2022

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality. October 4, 2022

Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. October 4, 2022

External Beam Radiotherapy With or Without Brachytherapy Boost in Men with Very High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. October 4, 2022

A patient-driven clinicogenomic partnership for metastatic prostate cancer. October 4, 2022

Page 1 of 1252

email news signup